Citadel Advisors’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding HBIO
WCM
MIM
NCNMGF
CCM
Citadel Advisors's HBIO Position: Q2 2026 in Review
Citadel Advisors opened a new position in Harvard Bioscience (HBIO) in Q2 2026: 13,251 shares worth $81.5K. The stake represents ﹤0.01% of the portfolio and ranks #12835 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in HBIO as recently as Q4 2025.
Citadel Advisors first reported a position in HBIO in Q2 2013 and has held it in 28 quarters since. The position peaked at $537K in Q2 2022. 37 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.
- Citadel Advisors held 13,251 shares of Harvard Bioscience worth $81.5K as of Q2 2026.
- Harvard Bioscience was a new Citadel Advisors position in Q2 2026.
- Harvard Bioscience made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12835 holding.
- Citadel Advisors first reported a position in Harvard Bioscience in Q2 2013 and has held it in 28 quarters since.
- Citadel Advisors's Harvard Bioscience position peaked at $537K in Q2 2022.
- 37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.